title: Controversies of the hormonal conservative treatment of endometrial cancer.
abstract: BACKGROUND
  Hysterectomy plus salpingo-oophorectomy represents the standard treatment for patients with well-differentiated endometrial cancer (EC) limited to the endometrium. It is estimated that over 5% of EC are diagnosed in nulliparous women aged 35-44 years. In addition, EC can affect obese women with diabetes, hypertension and other comorbidities increasing the surgical risk.
  
  
  METHODS
  This article reviews the English literature in PubMed regarding hormonal treatment of EC.
  
  
  RESULTS
  Use of hormonal therapies has resulted in complete remission in 60-70%; many of these women were able to achieve full-term pregnancies, and in case of contraindication to surgery, resection could be avoided. Several topics, however, such as patient selection, interobserver histologic evaluation, the type/duration of hormonal treatment, modality of evaluation before treatment and surveillance after treatment, which are still subject to controversy, are therefore discussed in this paper.
  
  
  CONCLUSIONS
  Uterus-sparing treatment of well-differentiated EC limited to the endometrium is feasible and has acceptable efficacy in women with increased surgical risk or those who wish to preserve their fertility. Although the methods applied to determine disease extent beyond the endometrium are still unsatisfactory, patient selection is a crucial factor determining the outcome of treatment. However, women must be fully informed about the possibility of treatment failure and the necessity of a close follow-up after therapy.
authors.affiliation: Gynecology Oncology Program, Hospital Universitario Madrid Sanchinarro, Centro Integral Oncológico Clara Campal, Madrid, Spain. lucasminig @ yahoo.com
authors.forename: Lucas
authors.initials: L
authors.lastname: Minig
authors.forename: Dorella
authors.initials: D
authors.lastname: Franchi
authors.forename: Javier
authors.initials: J
authors.lastname: Valero de Bernabé
authors.forename: Mario
authors.initials: M
authors.lastname: Sideri
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal